Abstract
Background —The goal of the study was to determine an association of ventricular substrate with thrombotic, cardioembolic, and hemorrhagic stroke.
Methods —Participants from the Atherosclerosis Risk in Communities study with analyzable ECGs and no history of stroke were included (n=14,479; age 54±6 y; 55% female; 24% black). Ventricular substrate was characterized by cardiac memory [spatial QRS-T angle (QRS-Ta), sum absolute QRST integral (SAIQRST), spatial ventricular gradient magnitude (SVGmag)], premature ventricular contractions (PVC) and tachycardia-dependent intermittent bundle branch block (TD-IBBB) on 12-lead ECG recorded at visits 1-5. Incident strokes were adjudicated by physician reviewers. Cox proportional hazard risk models were constructed.
Results —Over a median 24.5 y follow-up, there were 899 thrombotic, 400 cardioembolic, and 187 hemorrhagic strokes. After adjustment for cardiovascular disease (CVD) and its risk factors, atrial fibrillation / atrial substrate, and ECG-left ventricular hypertrophy, PVC (HR 1.72; 95%CI 1.02-2.92), QRS-Ta (HR 1.15; 95%CI 1.03-1.28), SAIQRST (HR 1.20; 95%CI 1.07-1.34) and time-updated SVGmag (HR 1.19; 95%CI 1.08-1.32) associated with cardioembolic stroke. After adjustment for CVD and its risk factors, PVC (HR 1.53; 95%CI 1.03-2.26), QRS-Ta (HR 1.08; 95%CI 1.01-1.16), SAIQRST (HR 1.07; 95%CI 1.01-1.14), and time-updated SVGmag (HR 1.11; 95%CI 1.04-1.19) associated with thrombotic stroke. In fully adjusted time-updated Cox model QRS-Ta (HR 1.20; 95%CI 1.04-1.38), SAI QRST (HR 1.23; 95%CI 1.06-1.43), SVGmag (HR 1.23; 95%CI 1.06-1.43) associated with hemorrhagic stroke, whereas TD-IBBB trended (HR 1.84; 95%CI 0.25-13.33).
Conclusions —PVC burden reflected by cardiac memory is associated with ischemic stroke. Transient cardiac memory (likely through TD-IBBB) precedes hemorrhagic stroke.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
not a clinical trial
Funding Statement
The Atherosclerosis Risk in Communities study has been funded in whole or in part with Federal funds from the National Heart, Lung, and Blood Institute, National Institutes of Health, Department of Health and Human Services, under Contract nos. (HHSN268201700001I, HHSN268201700002I, HHSN268201700003I, HHSN268201700004I, HHSN268201700005I). This work was supported by HL118277 (LGT).
Author Declarations
All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.
Yes
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The ARIC Study data are available through the National Heart, Lung, and Blood Institute's Biological Specimen and Data Repository Information Coordinating Center (BioLINCC), the National Center of Biotechnology Information's database of Genotypes and Phenotypes (dbGaP), and via ARIC Coordinating Center at the University of North Carolina-Chapel Hill.
